Immunomodulatory properties of protein hydrolysates by Kiewiet, Mensiena Berentje Geertje
  
 University of Groningen
Immunomodulatory properties of protein hydrolysates
Kiewiet, Mensiena Berentje Geertje
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Kiewiet, M. B. G. (2018). Immunomodulatory properties of protein hydrolysates. [Groningen]:
Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
9  
Immunomodulating properties of 
protein hydrolysates for application 
in cow’s milk allergy
1
M.B.G. Kiewiet1, M. Gros2, J. van Neerven2, M. M. Faas1, P. de Vos1
1Immunoendocrinology, Division of Medical Biology, Department of Pathology and 
Medical Biology, University of Groningen, University Medical Center Groningen, 
Hanzeplein 1, 9700 RB Groningen, The Netherlands
2FrieslandCampina, Stationsplein 4, 3818 LE Amersfoort, The Netherlands
Pediatric Allergy and Immunology, 2015, (26:3).
 10 
Abstract
Cow’s milk proteins cause allergic symptoms in 2-3 % of all infants. In these individuals the 
tolerogenic state of the intestinal immune system is broken, which can lead to sensitization 
against antigens and eventually to allergic responses. Although a true treatment for food allergy 
is not available, symptoms can be avoided by providing the infants with hydrolyzed proteins. 
Hydrolyzed proteins are proteins that are enzymatically degraded. They lack typical allergenic 
IgE-binding epitopes but are also thought to play a pertinent role in other mechanisms 
inducing hypoallergenic effects. This review discusses the mechanisms and evidence for 
immunomodulating properties of cow’s milk hydrolysates. Hydrolysates are found to strengthen 
the epithelial barrier, modulate T cell differentiation, and decrease inflammation. Some studies 
suggest a role for hydrolysates in manipulating pathogen recognition receptors signaling as 
underlying mechanism. Peptides from hydrolysates have been shown to bind to TLR2 and TLR4 
and influence cytokine production in epithelial cells and macrophages. Current insight suggests 
that hydrolysates may actively participate in modulating the immune responses in subjects 
with cow’s milk allergy and those at risk to develop cow’s milk allergy. However more research is 
required in order to design effective and reproducible means to develop targeting strategies to 
modulate the immune response.
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Immunomodulating properties of protein hydrolysates for application in cow’s milk allergy
Introduction
Awareness of food allergy as a serious health issue is increasing in the Western world. Its burden 
on morbidity, quality of life, and health care costs is more and more recognized [1, 2]. Despite this, 
there is a lack of treatment options. The only reliable therapy up to now is avoidance of allergens. In 
order to design more effective treatments, more insight is required in the mechanisms associated 
with food allergy.
 A type of food allergy that has been subject of many studies is cow’s milk allergy in infants. 
Infant formula, which is often cow’s milk based, is the only approved alternative for breast feeding. 
However, cow’s milk proteins cause allergic symptoms in 2-3 % of the infants [3]. These allergic 
symptoms can be avoided by providing the infants with so-called hydrolysates of cow’s milk 
protein instead of the intact proteins [4]. Peptides in hydrolysates possess different immunological 
properties which prevent allergy [5].
 The mechanisms by which hydrolysates modulate allergic responses are still subject of 
debate. One of the mechanisms is that after being taken up by intestinal epithelial cells and 
presentation of the peptides to the gastrointestinal immune system, the response is different and 
more tolerogenic than the response against the larger proteins [6]. The gastrointestinal immune 
system therefore seems to play an essential role. The barrier is composed of an epithelial layer and 
a variety of immune cells [7]. It is covered with mucus. The proteins and peptides are taken up 
by the epithelial cells and presented to the mucosal immune system. Here they interact with the 
gastrointestinal immune system (figure 1) to either induce tolerance or an immune response. In 
this review, we will give an overview on current knowledge on immunomodulatory properties of 
cow’s milk hydrolysates and its interaction with the mucosal immune system. In order to do this 
we will first discuss the immunological processes involved in maintaining oral tolerance and the 




Figure 1. Layers of the intestinal immune barrier. The barrier consists of a protective layer of epithelial cells covered 
with mucus and a range of immune cells. The main cell type in the epithelial layer are gate-keeping epithelial 
cells, but other specialized cells are also present. The crypts of the villi contain both mucus producing goblet cells 
and anti-bacterial compound secreting Paneth cells. The lamina propria under this epithelial layer contains many 
immune cells including dendritic cells, macrophages and lymphocytes. After antigen passed the epithelial barrier 
it is taken up by dendritic cells. The antigen presenting dendritic cells migrate to the mesenteric lymph nodes and 
presented their MHC-antigen complex to T cells inducing T cell activation. In the small intestine Peyer’s patches are 
present. In these organized lymphoid nodules antigen presenting dendritic cells also interact with T cells. T cells 
then regulate the immune response activating other immune cells, for example B cells.
Large proteins can cause allergy in infants
Newborns have specifi c dietary needs. To achieve optimal growth, development and health in 
the fi rst months of life, breast milk is required. When breastfeeding is not possible, infant formula 
is the only approved infant nutrition. However, this is not without consequences. Infants are not 
yet able to digest all the novel enteral nutrients. The immature infant’s digestive system is not 
producing enough enzymes essential for protein digestion, such as gastric pepsin [8]. Also, the 
relatively high pH in the infant’s stomach does not accommodate optimal digestion of proteins 
[9]. This results in partly or undigested proteins in the gastrointestinal tract of the infant during 
a vulnerable period for the development of food allergy. As a result, more and larger proteins 
may pass the gastrointestinal barrier and induce, in the presence or absence of a pathogen, an 




 Furthermore, an important characteristic of the infant’s intestine is the relatively high 
permeability of the epithelial layer separating the intestinal lumen from the mucosal immune 
system [11], which is associated with allergic reactions [11]. This can also contribute to a higher 
uptake of larger proteins, although it is more related to the later allergic reactions than to the 
sensitization phase.
 In order to understand where and how food allergy against proteins can develop, we first 
need to discuss the comprehensive regulatory system that is involved in tolerance induction.
The gastrointestinal epithelial cells as gatekeeper
The first line of defence against intruders are, as outlined above, the epithelial cells separating the 
intestinal lumen from the mucosal immune system. The epithelial cells are highly organized and 
connected by tight junctions on both the apical and basolateral site. In adults, the connections 
make the barrier impermeable for molecules larger than 3,5 kDa [12]. For infants, the exact 
permeability for macromolecules is not known, and depends on birth weight, gestational 
and postnatal age [13]. Epithelial cells carry the polymeric Ig receptors on the basolateral side 
which continuously transport neutralizing IgA antibodies into the lumen, which bind to harmful 
antigens that are then expelled by the peristaltic process [12].
 The permeability of the epithelial layer is variable over time. Binding of food components 
to immune-related receptors can actively increase and decrease permeability to sample 
antigens from the lumen [14]. Such receptors are for instance pattern recognition receptors 
(PRRs), including Toll-like receptors (TLRs) [15]. Binding of a luminal antigen to PRRs can lead to 
release of serine-proteases such as zonulin by epithelial cells [16]. These serine-proteases digest 
the tight junctions between epithelial cells [17], which leads to an increase in permeability and 
consequently entry of luminal antigens in the lamina propria (figure 2). How often this occurs and 
how it quantitatively contributes to tolerance for specific food antigens is unknown.
 Another, more in detail-studied process, is antigen sampling by dendritic-like cells that 
are located in between the epithelial cells. These dendritic cells, often referred to as the 
CD11b+CX3CR1+ cells create protrusions into the lumen of the gastrointestinal tract to sample 
its contents [18]. The major part of luminal antigen sampling, however, is not occurring by the 
epithelial or dendritic cells but in the gut-associated lymphoid tissues (GALT). In the small intestine 
these are called the Peyer’s patches. Here, specialized epithelial cells called M-cells transport 
luminal antigens to the underlying dendritic cell-rich area [19]. Here the antigens are taken up by 
antigen presenting cells (APC) (mainly dendritic cells) and processed for presentation to T cells. 
These dendritic cells are referred to as the CD103+CX3CR1-. They are found in high quantities 
in the lamina propria and take up food components, including proteins, that are sampled by 
the epithelial cells or CD11b+CX3CR1+ dendritic cells. Currently, the CD103+CX3CR1- dendritic 
cells are considered to be the only dendritic cell population that is able to migrate to mesenteric 
lymph nodes [20], to induce tolerogenic responses. In order to do so the cells need appropriate 
tolerogenic signals. An important source of tolerogenic factors are the epithelial cells [21]. When 
the epithelial cells secrete factors such as IL-10, TGF-β, and TSLP [21], CD103+CX3CR1- dendritic 
cells differentiate into tolerogenic dendritic cells, before presenting their antigens to T cells in the 
mesenteric lymph nodes.
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Figure 2. The intestinal epithelium separates the lumen of the intestine from the lamina propria and the 
immune system. It keeps pathogens and antigen from entering the body. This layer of epithelial cells is covered 
by a thick layer of mucus. The mucus layer is a reservoir for IgA, which agglutinates peptides. This stimulates 
expelling of the peptides. Epithelial cells are joint together by tight junctions. These structures, consisting mainly of 
the proteins ZO-1, occludin and claudin, make the paracellular spaces impenetrable for most proteins. However, 
the permeability of the epithelial layer is not always that low. Epithelial cells express receptors including MHC class 
II and pattern recognition receptors. Binding of food derived molecules to these receptors is able to regulate the 
permeability.
Adaptive tolerogenic T cell responses to food antigens
Depending on the amount of antigen, three distinct immunological mechanisms can contribute 
to immunological tolerance to food antigens: i.e. induction of regulatory T cells (Tregs), clonal 
anergy of T cells, and deletion of T cells [21]. Tregs are mainly generated by CD103+CX3CR1- 
dendritic cells in the mesenteric lymph nodes. Here the tolerogenic CD103+CX3CR1- dendritic 
cells present the food antigens to CD4+ T cells. Tolerogenic CD103+CX3CR1- dendritic cells, but 
also macrophages, mostly express IL-10, and TGF-β, which induce Treg formation [22]. Upon 
interaction of dendritic cells with the Treg subtype Th3, a cascade of Treg subtype induction and 
maintenance is initiated, while the secreted TGF-β at the same time inhibits Th1 and Th2 subtype 
T cells [21]. This type of tolerance induction is only initiated when the food antigen is present in 




 At higher doses tolerance is mainly caused by clonal deletion and clonal anergy. PRR mediated 
activation, and especially TLR signaling, has also been found to be essential in these processes. 
TLRs have been shown to function as co-stimulatory molecule in the interaction between T cells 
and dendritic cells [23]. By this, TLRs infl uence the T cell response, as peptide-MHC-II-complex 
presentation together with a lack of co-stimulatory molecules on dendritic cells during high 
antigen exposure is thought to cause T cell clonal anergy [24]. Clonal deletion of T cells is the 
other process that occurs at high antigen exposure. This usually occurs in the Peyer’s patches. It 
is thought to be caused by natural killer T cells, possibly via Fas-FasL interaction with T cells that 
leads to apoptosis of food antigen recognizing T cells [25] (fi gure 3).
Figure 3. Mechanisms of oral tolerance induction. In a normal situation immunity is induced by the interaction 
between an antigen presenting dendritic cell and a naïve T cell. Due to the binding of the TCR (T cell receptor) with 
the MHC-peptide complex and the costimulatory molecules the T cell gets activated. However, the default state in 
the gut is tolerance against dietary antigens. Diff erent mechanisms are involved in inducing tolerance. When a 
high dose of antigen is present, the main mechanisms involved are anergy and deletion of T cells. Anergy occurs 
when costimulatory molecules are lacking during the interaction between dendritic cells and T cells. This leads to 
an unresponsive T cell. Deletion also occurs at high-antigen levels. Antigen specifi c T cells go into Fas-Fasligand 
induced apoptosis after interacting with for example a natural killer T cell. The main mechanism inducing tolerance 
at a low dose of antigen is the induction of regulatory T cells. Tolerogenic factors produced by epithelial cells result 
in a more tolerogenic dendritic cell. When this cell interacts with a T helper 3 cell, the T cell produces TGF-β, which 
leads to diff erentiation towards a regulatory T cell and the inhibition of Th1 and Th2 cells.
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Food allergy through broken tolerance
Sensitization to a food antigen may occur, when one of the above mentioned processes fails. The 
antigen, such as a food protein, then causes an inappropriate Th2 skewed immune response. In 
the sensitization phase antigens are processed by APCs and presented to T cells. These T cells 
become activated Th2 cells, which stimulate class switching to IgE and B cell diff erentiation into 
B plasma cells by secreting a mix of cytokines, including IL-4, IL-5, and IL-6 [26]. The antigen-
specifi c IgE antibodies bind to the high-affi  nity IgE receptor FcεRI on mast cells and basophils. 
Re-exposure to the same antigen results in cross-linking of the IgE antibodies bound to FcεRI, 
inducing degranulation of the mast cells, which causes an immediate hypersensitivity reaction 
[27]. Mast cells release several infl ammatory mediators including histamine, which contributes to 
clinical symptoms like nausea, vomiting, and abdominal pain [27] (fi gure 4). Upon activation, mast 
cells also secrete chymases, and various cytokines, such as TNFα, IL-13, and IL-8 [28], that can break 
open the tight junctions between epithelial cells, which allows more dietary antigens to cross 
the epithelial barrier. These changes in barrier function after antigen exposure lead to changes 
in osmotic water pressure over the epithelial barrier with diarrhea as a consequence [29]. When 
the barrier cannot be closed, the result will be severe infl ammation which subsequently leads to 
more epithelial breakdown.
 The immediate hypersensitivity reaction can be followed by a T cell mediated late phase 
response, which occurs 12-48 hours after antigen exposure [30] and is caused by the continuous 
presence of antigen [31]. During this late phase reaction, Th2 cells and intestinal epithelial 
cells keep producing Th2 related cytokines such as IL-4, IL-5, IL-9, and IL-13 [28]. This leads to 
maintenance of high IgE levels, elevated mucus production and the infi ltration of basophils, 
eosinophils and lymphocytes [32].
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Figure 4. Overview of the events during sensitization and an allergic reaction. When antigen passed through 
the epithelial barrier it is taken up and processed by antigen presenting cells (APCs). These cells present the antigen 
in a MHC class II molecule together with costimulatory molecules to antigen specific naive T cells, which get 
activated and develop a Th2 phenotype. Activated T cells stimulate B cell differentiation into plasma cells, which 
start to produce antigen specific antibodies (IgE). These antibodies bind to the high-affinity receptor Fc3RI on mast 
cells. Upon re-exposure of the same antigen the antibodies cross-link and degranulation of the mast cell is induced. 
The release of a range of compounds results in allergic symptoms.
Beyond Th1 and Th2 cells
Although food allergy was classically thought to be a Th2 type response, recent studies have 
shown that the Th1/Th2 paradigm is an oversimplified view of the real situation. Besides Th1 and 
Th2 T cells, other T cell subtypes, such as Th17 and Th22, have been identified and found to be 
important in gut homeostasis [33]. In healthy individuals, low numbers of Th17 cells are present, 
mainly in the lamina propria [34]. During infection IL-17 induces the recruitment of neutrophils, 
and the epithelial increase of chemokine CCL20 attracts more Th17 cells [35]. Current insight 
suggests Th17 cells also play a role in cow’s milk allergy as will be outlined below.
 Th22 cells produce IL-22. IL-22 has been found to be essential in the defence against Gram-
negative bacteria in the intestine [36], showing its important role in the regulation of host defence 
and homeostasis. IL-22 elicits these protective effects by inducing for example the expression of 
antimicrobial peptides [36].
 The above suggest that both Th17 and Th22 cells are important in maintaining homeostasis 
in the intestine and thus protect the state of tolerance. Although it is well established that these 
cells play a role in other allergic diseases, such as allergic airway inflammation [37], their exact 
role in cow’s milk allergy needs more attention of researchers. Earlier, a trend towards a negative 
correlation between whole blood IL-17 levels and sensitization to some food antigens was 
described [38], which is in line with the study of Duhban and d’Hennezel who found a lower 
production of IL-17 in CD4+ T cells in children with food allergies compared to healthy controls. 
In vitro, CD4+ T cells from these allergic children showed impaired IL-17 production after antigen 
administration [39].
Possibility to prevent/treat allergy with hydrolyzed proteins
As outlined before allergic reactions against cow’s milk protein in cow’s milk allergic infants can 
be prevented or avoided by administration of hydrolysates of cow’s milk. During hydrolysis of 
the original protein, mixtures of smaller peptides with different properties can be produced. The 
formulas available differ by the degree of hydrolysis. There are extensively or partially hydrolyzed 
formulas available, made from whey or casein. Extensively hydrolyzed formulas are intended to 
avoid allergic reactions in already cow’s milk allergic infants. This hypoallergenic effect has longer 
been known to be due to the destruction of the epitopes on the proteins, which are responsible 
for IgE binding [41]. Partially hydrolyzed formulas are used for infants at risk for developing food 
allergy [40], and are (together with extensively hydrolysates) now more and more considered to 
be hypoallergenic by modulating the immune response and therewith preventing sensitization. 
Some peptides in hydrolysates (but also proteins in cow’s milk) have indeed been described 
Immunomodulating properties of protein hydrolysates for application in cow’s milk allergy
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to actively influence the immune system and modulate the allergic response [42]. When 
encountering the epithelial cells and CD11b+CX3CR1+ dendritic cells in the intestine peptides 
can bind to specialized PRRs involved in inducing tolerogenic responses [43]. By binding to the 
receptors, which are able to recognize a variety of molecules, hydrolysates may be able to affect 
the epithelial barrier or the dendritic cells.
 Jaziri et al. already proved in 1992 the concept of peptides binding to specific receptors [44]. 
They showed that the immunostimulating peptides Gly-Leu-Phe (GLF) and Val-Glu-Pro-Ile-Pro-
Tyr (VEPIPY), which were isolated from casein, bound to specific sites on human phagocytic 
blood cells. Although the binding sites were not further characterized it was thought that the 
two investigated peptides were recognized by two different receptors. GLF bound specifically 
to monocytes and polymorphonuclear leukocytes, while VEPIPY only bound to monocytes 
and macrophages. By using different analogues, the great selectivity of the binding sites was 
demonstrated. Iskander et al [45] recently observed a decline in the LPS-induced IL-8 production 
in respiratory epithelial cells after the administration of whey protein hydrolysates. When they 
studied the mechanism involved, they found that the hydrolysate did not suppress the IL-1β 
and TNFα but induced IL-8 production. Therefore TLR4, which binds LPS, was suggested to be 
involved. It was demonstrated that the hydrolysate did neither neutralize LPS nor change the 
expression of the TLR4 receptor. Therefore, it was concluded that the effect of the hydrolysate was 
probably due to a direct binding of the hydrolysate to the TLR4 receptor, thereby preventing the 
binding of LPS. However, hydrolysates may not only hinder the binding of inflammatory stimuli to 
TLR receptors, they may also directly activate TLR signaling [46]. Inhibition of either TLR2 or TLR4 
was shown to abolish the increased production of IL-6 in intestinal epithelial cells treated with a 
yellow pea protein hydrolysate [46].
Hydrolysates affect the intestinal epithelial barrier
Up to now there are a few studies dedicated to modulation of the barrier function by hydrolysates. 
Visser et al. [47, 48] fed diabetes prone rats casein hydrolysates from the moment of weaning until 
an age of 140 and 150 days and compared the barrier function of these animals with animals 
fed regular chow with the same macronutrient composition [47, 48]. The in vivo barrier function 
improved as demonstrated by a decrease in the lactulose:mannitol ratio in both studies [47, 48]. 
Also in vitro the intestinal barrier was increased by hydrolysates, as demonstrated by measuring 
the transepithelial electrical resistance (TEER) of a sample from the ileum [48]. Looking further 
into the mechanisms involved in the improvement of the epithelial barrier, it was found that 
the mRNA expression of genes encoding the tight junction proteins myosin IXb, claudin-1, and 
claudin-2 in diabetic rats on casein hydrolysates were normalized in the ileum after the casein 
hydrolysate diet compared to healthy rats, together with an upregulation of the regulatory 
cytokine IL-10 [48]. These studies demonstrate that hydrolysis not only deletes allergic epitopes 
but that hydrolysates also stimulate immune barrier function. Interestingly, one of these studies 
compared the hydrolysate formulation with a formulation containing only single amino acids 
[47], and found that the hydrolysate formulation was superior in epithelial barrier protection. This 
underscores the important role of peptides present in the hydrolysate mixture.
 Hydrolysates may also influence the ‘inflammatory’ status of the epithelial cells, and since 
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inflammation is associated with cell damage and consequently damage to the epithelial barrier, 
hydrolysates can affect the epithelial barrier via this way. This was shown by Nielsen et al. who 
studied the inflammatory state of intestinal epithelial cells in vitro by using intestinal epithelial 
cells treated with the inflammation inducing drug indomethacin [49]. Casein treated with the 
enzymes pepsin and corolase was observed to decrease the transcription of several inflammation 
markers, including cyclo-oxygenase 2 (COX-2) and nuclear factor kappa beta (NF-κB), compared 
to casein treated with pepsin only, suggesting an anti-inflammatory effect of this hydrolysate 
[49]. Hydrolysates from other sources can also cause anti-inflammatory effects. For instance, a 
hydrolysate obtained from pea protein was observed to decrease the production of IL-8, which 
is a proinflammatory cytokine, in Caco-2 cells compared to an unhydrolyzed pea protein extract 
[50]. However, this hydrolysate also inhibited epithelial cell division, and thereby hindered normal 
epithelial cell renewal and decreased epithelial integrity.
 Hydrolysates thus appear to be able to stimulate the epithelial barrier. Because an increased 
permeability of the intestines is associated with intolerance and food allergy [51], an improved 
epithelial barrier is beneficial in at-risk or already allergic infants. Therefore, peptides that improve 
the epithelial barrier are expected to have a hypoallergenic effect. It is therefore important that 
further (mechanistical) studies into the effect of hydrolysates on the intestinal epithelial barrier 
are performed.
Hydrolysates show anti-inflammatory effects in innate immune cells, which can influence 
macrophage differentiation and the allergic reaction against dietary proteins. 
Hydrolysates have also been shown to inhibit inflammatory responses and even stimulate 
tolerogenic responses in antigen presenting cells. Oseguera-Toledo [52] used a hydrolysate 
mix from the common bean (Phaseolus vulgaris L.) obtained from hydrolysis using the enzymes 
alcalase and pepsin-pancreatin. After administrating the hydrolysate, LPS activated RAW 264.7 
macrophages showed a decrease of inflammation markers, such as COX2 expression and 
related prostaglandin E2 production, inducible NO synthase (iNOS) expression and related NO 
production. The decrease of these inflammation markers was associated with a decrease of NF-
κB, due to a decreased translocation of its subunits p50 and p65 [53]. However, these results 
were not compared to the intact protein extract from the common bean. Similar results for p50 
and p65 were found when using a peptide called lunasin or a lunasin-like peptide, which was 
obtained from soy [54]. Interestingly, this is one of the few peptides to be studied as individual 
protein giving unique insight in structure- function relationships. Lunasin was found to inhibit 
NO, prostaglandin E2, iNOS, and COX2 as well. Furthermore, the proinflammatory cytokines IL-6 
and IL-1β, which are also under the control of NF-κB, were also found to be reduced.
 Combined, the foregoing studies suggest that in addition to improving barrier function, 
peptides in hydrolysates may contribute to preventing allergy by inducing a more tolerogenic 
response in antigen presenting cells. In vitro studies suggest that a decreased overall amount of 
NF-κB and in particular the p50 subunit regulate the polarization of macrophages away from a 
pro-inflammatory (M1) towards an alternative (M2) state, which are directed towards a regulatory 
and tissue repair function [55] (figure 5). Therefore, the anti-inflammatory peptides could also 
help to control inflammation in the late phase of the allergic reaction [56].
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 Performing paw oedema tests in mice fed with hydrolysates indeed showed that diff erent 
whey hydrolysates have anti-infl ammatory eff ects in vivo, which is promising in a setting of cow 
milk allergy [57].
Figure 5. Immunomodulating peptides might be able to stimulate M2 diff erentiation in macrophages by 
regulating the expression of the NF-κB subunits p50 and p65. Specifi c peptides are able to decrease the overall 
NF-κB activity in the cell, which leads to a more M2 type macrophage. TLR2 activation for example results in 
autophagy of both p50 and p65. Administration of peptides that change the expression of a particular subunit can 
also change the phenotype of the macrophages. This results in a diff erent amount of regulatory NF- κB complexes 
containing a p50 homodimer. This complex stimulates the expression of genes related to an M2 phenotype and 
inhibits the expression of multiple M1 genes.
Specifi c hydrolysates skew the T cell diff erentiation from a Th2 subtype towards Th1 or Treg, 
which is benefi cial in food allergy.
Peptides from hydrolysates may also encounter lymphocytes in the lamina propria when passing 
the barrier. Especially in infants where the epithelial barrier is rather permeable [11] this is likely. 
Many studies have shown that hydrolysates from diff erent sources can have a direct stimulatory 
eff ect on the proliferation and activation of lymphocytes. For example, hydrolysates obtained 
from soy and whey (or more specifi cally the proteins β-lactoglobulin or lactoferrin) were shown 
to enhance proliferation in murine spleen lymphocytes [58]. Also intact whey proteins stimulate 





Although the above-mentioned results show an effect of hydrolysates on number of lymphocytes, 
it is not the number of lymphocytes that may prevent or inhibit an allergic response, but the 
skewing of Th2 responses towards Th1 responses [60]. These T cell responses can be induced 
without causing an allergic response, depending on the size of the peptides in the hydrolysate. 
For IgE crosslinking the peptides need a minimal length of 30 amino acids. Smaller peptides are 
not able to induce mast cell degranulation, but can still be recognized by T cells and therefore 
skew T cell differentiation [61].
 Only a few studies have addressed this issue of T cell differentiation skewed by peptides at 
the moment. One study investigated the effect of a yak milk casein hydrolysate on the Th1/Th2 
balance by measuring mRNA levels of Th1 cytokines (IL-2 and IFN-γ) and the Th2 cytokine IL-4 in 
murine spleen lymphocytes [62]. They found that this hydrolysate increased the Th1 cytokines, 
but it did not alter IL-4 levels. Therefore, this specific hydrolysate skewed the differentiation of T 
cells towards a Th1 subtype. Furthermore, Wu et al. mentioned that the IFN-γ/IL-4 ratio increased 
in spleen T cells from mice fed with chitosan hydrolysate, suggesting a change towards a more 
Th1-like phenotype [63]. On the contrary, specific hydrolysates derived from whey did not show 
individual effects on specific cytokines [61].
 Because IL-10 producing Treg cells can inhibit Th2 cells, another way to dampen the Th2 
response is to promote the differentiation of Treg cells by administration of specific peptides 
[31]. Various studies have shown an effect of hydrolysates on Treg formation by showing an IL-
10 upregulation after treatment of lymphocytes with a hydrolysate obtained from the seaweed 
Porphyra columbina [64] or from casein hydrolysate [65]. This upregulation of IL-10 production 
was also observed in splenocytes obtained from mice treated with β-lactoglobulin trypsin 
hydrolysates, while intact β-lactoglobulin on the contrary downregulated IL-10 [66]. Ndiaye et al. 
also found an increased amount of IL-10 producing cells in the small intestine lamina propria of 
mice after oral administration of yellow pea protein hydrolysate [46].
 Hydrolysates are not only thought to elicit effects on the epithelial barrier by binding to 
TLRs, but the observed effects on lymphocytes described above could also be induced via TLRs 
expressed on dendritic cells and T cells. TLR activation not only induces tolerogenic dendritic 
cells, but in general, activation of TLRs on antigen-presenting cells also prevents a Th2 driven 
allergic response by skewing a more Th1 like response [67]. Multiple animal studies have indeed 
shown that stimulation of a range of TLRs ameliorates the allergic response, including TLR2, 
TLR3, TLR4, TLR5, TLR7, and TLR9 [68]. Some clinical studies using non-pathogenic probiotics as 
TLR ligand showed a decrease in the incidence of atopic dermatitis, although the number of 
sensitized individuals was the same in the placebo and the experimental group [69]. However, 
although effects of hydrolysates on TLR signaling in epithelial cells [45] and effects of hydrolysates 
on dendritic cell and T cell activation and proliferation have been shown, more research is needed 
to show the direct interaction of hydrolysate peptides and TLRs on dendritic cells and T cells.
Conclusion and future perspectives
In order to prevent immune reactions against the numerous antigens present in the lumen of the 
gut, the different arms of the intestinal immune system contribute to maintaining a tolerogenic 
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state. When this state of tolerance is broken, this can lead to the onset of an allergic reaction. 
The present review discusses the evidence that although dietary proteins may serve as allergic-
antigens, some bioactive peptides from hydrolysates have the ability to modulate the immune 
response in a hypoallergenic or other beneficial way [70].
 An important part of these beneficial effects is attributed to the immunomodulatory 
properties of the hydrolysates [71]. There is increasing in vitro evidence that hydrolysates contain 
specific immunomodulating peptides, which, possibly by binding to TLR, have been found to 
improve the epithelial barrier, modulate the Th1/Th2 balance and the amount of Tregs towards 
a less Th2 skewed response and decrease inflammation. The limited in vivo studies confirm these 
findings (table 1). However, to get a better understanding of the immunomodulatory effects of 
hydrolysates especially human studies are needed, since many different effects of peptides, of 
both a pro- or anti-inflammatory nature, were found, which makes it hard to predict the final 
outcome in humans.
 Another complicating factor is the diversity and a lack of documentation of the chemical 
properties of the hydrolysates tested, making side-by-side comparison of studies complicated. 
Every hydrolysate composition, and therefore its effects, is unique due to the use of different 
raw materials and hydrolysis production methods. Therefore, general statements about 
the hypoallergenic and immunomodulating effects of hydrolysates are not possible. Our 
recommendation is to document as many details as possible about the hydrolysates, including 
their degree of hydrolyzation, the source, lot-number and way of processing. It is also important 
to isolate individual peptides from hydrolysates and study characteristics of these individual 
peptides separately, in order to elucidate the exact interaction between a specific peptide and 
e.g. a receptor.
 Hydrolyzed proteins are already used in infant formula for infants with cow’s milk allergy 
or infants at high risk to become allergic. However, up to now the suitability of these peptides 
in cow’s milk allergy is based on observations of absence of symptoms in the infants treated, 
while the underlying mechanisms are not well understood. Elucidating the exact effects and 
working mechanisms of specific peptides together with a better understanding of tolerance 
induction could provide mandatory information for a more efficient application of specific 
immunomodulating peptides in order to induce a hypoallergenic effect in infants. Therefore, 
more knowledge about the hypoallergenic effects of these hydrolysates will contribute to a more 
efficient treatment of this vulnerable group of newborns, and could ultimately also be beneficial 




Reference Author(s) Year of 
publication
Described effects Type of studie Species in vivo 
studies
45 Iskander et al 2013 Decline in the LPS-induced IL-8
production in respiratory epithelial cells 
after the administration of whey protein 
hydrolysates
In vitro -
49 Nielsen et al. 2012 Decrease in expression of 
inflammation markers in casein 
hydrolysate treated epithelial cells
In vitro -
50 Swiatecka et 
al.
2012 Hydrolyzed pea protein decreased IL-8




2011 LPS activated macrophages showed a 
decrease of  inflammation markers 
after administration of hydrolyzed
common bean protein
In vitro -
54 de Mejia 2009 Lunasin inhibited inflammatory 
markers and reduced the production of 
IL-6 and IL1β in macrophages
In vitro -
58 Wong et al 1989 Whey hydrolysates enhanced
proliferation in murine spleen 
lymphocytes
In vitro -
61 Knipping et al. 2012 Whey hydrolysates did not show 
individual effects on specific cytokines
In vitro -
62 Mao et al. 2007 Yak milk hydrolysate increased Th1 
cytokine expression, but did not affect 
Th2 cytokines
In vitro -
64 Cian et al. 2012 A seaweed hydrolysate increased IL-
10 production in splenocytes, 
macrophages and T cells. 
In vitro -
65 Lahart et al. 2011 A casein hydrolysate increased IL-10
production in T cells.
In vitro -
66 Duan et al. 2012 β-lactoglobulin trypsin hydrolysates 
increased IL-10 production in 
splenocytes from sensitized mice
In vitro -
46 Ndiaye et al. 2012 Increased amount of IL-10+ cells in the 
small intestine lamina propria after oral 
administration of yellow pea protein 
hydrolysate
In vivo mice
47 Visser et al. 2012 Decreased in  lactulose:mannitol ratio 
(also compared to AA diet) after 
casein hydrolysate diet
In vivo rats
48 Visser et al. 2010 After casein hydrolysate diet
- decreased
lactulose:mannitol ratio 
- increased transepithelial 
electrical resistance in an 
ileum sample (ex vivo)
- mRNA expression tight 




57 Tavares et al. 2013 Anti-inflammatory effects from a whey 
hydrolysate were observed using a 
paw oedema test
In vivo mice
63 Wu et al. 2006 IFN-γ/IL-4 ratio increased in spleen T 
cells from mice fed with chitosan
In vivo mice
Table 1. Overview recent studies investigating immunomodulating effects of hydrolysates
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Rational and outline of the thesis
As outlined in the preceding section, hydrolysis of intact proteins is a promising method for the 
generation of bioactive proteins and peptides with effects on different layers of the immune 
system. However, a thorough and broad screening of immune effects of different hydrolysates 
is still lacking. Furthermore, the underlying mechanisms of the immune effects are not known 
yet. Therefore, the aim of the studies described in this thesis is to investigate how a range of 
hydrolysates of different sources affect epithelial and immune cells involved in the allergic 
reaction. We tested hydrolysates from cow’s milk proteins, which is the main source of proteins 
used in infant formulas, as well as hydrolysates from soy and wheat, which are used as alternative 
plant protein sources. Hydrolysates with different degrees of hydrolysis were compared. The data 
obtained in these studies contribute to better insights in the effects of hydrolysates on food 
allergy and will ultimately lead to the design of better and more tailored hypo-allergenic infant 
formulas.
 Since an extensive comparison of the effects of multiple hydrolysates is lacking, in chapter 2 
we performed a detailed screening of a broad range of cow’s milk hydrolysates for their possible 
activating effects on immune cells. Then, we investigated whether the effects of cow’s milk 
hydrolysates could be due to interaction of the hydrolysates with Pathogen Recognition Receptors 
(PRRs). We studied the Toll-like receptor (TLR) interacting capacity of hydrolysates of two fractions 
of cow’s milk proteins, whey and casein, and investigated whether the degree of hydrolysis of the 
hydrolysates with the same protein source influenced the observed effects. In chapter 3 we did 
the same experiments for soy and wheat hydrolysates, to screen immune effects derived from 
plant-based hydrolysates and discuss basic immunomodulatory differences between animal and 
plant source hydrolysates.
 As dietary molecules in the lumen of the intestine have been described to be able to modulate 
the epithelial barrier, in the next chapter, we studied effects of hydrolysates on the intestinal 
epithelial barrier. Therefore, in chapter 4 we studied the potential protective effects of hydrolysates 
on the epithelial barrier after disruption of the barrier by the disrupter A23187. After an extensive 
screening of epithelial barrier effects of cow’s milk, soy and wheat hydrolysates, we used soy 
hydrolysates, since strongest effects were observed in a hydrolysate from this protein source. The 
most potent soy hydrolysate was used to further investigate the effects of the soy hydrolysate 
on tight junctions. Furthermore, we studied the specificity and underlying mechanism of the 
protective effect by comparing the barrier protection after administering disruptors acting via 
different mechanisms.
 In the previous chapters, we studied the effects of hydrolysates on immune cells and epithelial 
cells in monocultures. In a physiological setting, the interaction between the different cell types is 
crucial for the outcome. Therefore, in chapter 5, we first studied the interaction between dendritic 
cells and epithelial cells after hydrolysate administration in vitro by using a transwell coculturing 
system. In this experiment we compared the effects of a whey and soy hydrolysate which were 
both found to be potent TLR activating hydrolysates in chapters 2 and 3. Then, we investigated 
the effects of soluble factors produced by dendritic cells and epithelial cells on T cells.
 During hydrolysis of intact proteins a complex mixture of many different proteins and peptides 
is formed. To determine effector-function relationships, it is important to identify the active 
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protein or active protein fraction in the hydrolysate that is responsible for the effects observed. 
Therefore, in chapter 6 we fractionated the mildly hydrolyzed whey and soy hydrolysates based 
on molecular mass, and tested the TLR activating potential of the fractions obtained. Next, 
the protein structures in the size defined fraction found to induce TLR activation were further 
characterized. Polyacrylamide gel electrophoresis (PAGE) was used to visualize the protein fraction 
responsible for TLR modulation, and by applying different PAGE conditions we determined the 
molecular forces and bonds involved in the tertiary and quaternary protein structures responsible 
for immune modulation. In order to maintain its immunomodulatory effect in vivo the protein 
fraction should withstand the harsh conditions and digestive enzymes in the stomach and 
intestine. We therefore also assessed the fate of hydrolysates during digestion in an in vitro infant 
digestion model.
 In chapter 7 the immune effects of a partially hydrolyzed whey protein in a cow’s milk allergy 
mouse model were studied. In order to investigate the sensitizing capacity of the hydrolysate 
tested, animals were first sensitized with the whey hydrolysate, followed by an intradermal 
challenge with intact whey after which the clinical symptoms were measured. To gain more 
insight in the immunological effects underlying the clinical outcome of sensitizing with a partial 
whey hydrolysate, we studied immune cell populations both in the systemic and intestinal 
immune organs after an oral whey challenge. In this way, we were able to determine a possible 
mechanism explaining the observed clinical outcome of whey hydrolysate sensitization.
 During our screening of the immune effects of a wide range of hydrolysates, we observed 
specific effects of a wheat hydrolysate that could have a beneficial effect on the intestinal health 
of adults as well and might serve specific purposes in medical nutrition. One such field is providing 
nutrition and suppressing inflammation in cancer patients on chemotherapeutics and suffering 
from mucositis or ileitis. Mucositis is inflammation of the mucosal intestinal tissue, which is 
initiated when PRRs are activated by danger signals released by chemically injured epithelial cells. 
Especially TLR2 is involved. During our screening for TLR interacting capacities of hydrolysates, we 
observed a strong TLR2 inhibitory effect of a wheat hydrolysate. Therefore, to take a first step in 
the development of wheat hydrolysates that might be effective in mucositis or ileitis, in chapter 8 
we investigated the TLR2 inhibitory effects of different wheat hydrolysates and the underlying 
mechanism. We also identified the peptides present in the hydrolysate that could be involved in 
the observed effects.
 Ultimately, an overall summery and discussion of the results in this thesis is available in chapter 9. 
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